Antithrombotic effects of 3-([1:1',2':1"]-3'-terphenyl)propanol in animals.
3-([1:1',2':1"]-3'-Terphenyl)propanol (CAS 186835-06-3, F050) and acetylsalicylic acid (ASA) inhibited platelet aggregation induced by CaCl2, arachidonic acid, collagen, adenosine diphosphate (ADP) and thrombin in guinea pigs, rabbits and rats in vitro. However, F050 had a wider spectrum of actions than ASA. Orally administered F050 inhibited platelet aggregation ex vivo. F050 significantly reduced the thrombus formation in the extracorporeal circulation thrombosis model in guinea pigs. It inhibited erythrocyte hemolysis induced by hypotonic NaCl, while ASA did not. F050, but not ASA, inhibited increases in platelet [CA2+]i caused by thrombin in guinea pigs. F050 is a parent compound that will facilitate the development of an orally active drug for the treatment of thrombotic diseases.
Hongou
K
K
Research Institute, Fuji Chemical Industries Co., Ltd., Toyama, Japan.
Miyamae
T
T
Hashizume
H
H
Oshima
K
K
Ogawa
T
T
Hongou
T
T
Morikawa
T
T
Hagiwara
M
M
D000818:Animals; D002118:Calcium / Q000097:blood; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors; D020005:Propanols / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D013730:Terphenyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D020005:Propanols; D013730:Terphenyl Compounds; C110049:F 050; D002118:Calcium